UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
May 9, 2017
Date of Report (Date of earliest event reported)
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
Ireland | 001-33500 | 98-1032470 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland
(Address of principal executive offices, including zip code)
011-353-1-634-7800
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company □
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □
Item 2.02. Results of Operations and Financial Condition.
On May 9, 2017, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended March 31, 2017. A copy of the Press Release is furnished as Exhibit 99.1 to this current report.
The information in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) | Exhibits |
Exhibit Number | Description |
99.1 | Press Release dated May 9, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY | ||
By: | /s/ Matthew P. Young | |
Name: | Matthew P. Young | |
Title: | Executive Vice President and Chief Financial Officer | |
Date: May 9, 2017
EXHIBIT INDEX
Exhibit Number | Description |
99.1 | Press Release dated May 9, 2017. |
Exhibit 99.1
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2017
FINANCIAL RESULTS
Total Revenues Increased 12% to $376 Million
Settled Xyrem Patent Litigation with First ANDA Filer
Completed Rolling NDA Submission for Vyxeos (CPX-351)
Announced Positive Top-Line Data for JZP-110 in Obstructive Sleep Apnea and Narcolepsy and for Xyrem in Pediatric Narcolepsy
DUBLIN, May 9, 2017 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2017 and updated financial guidance for 2017.
“The first part of 2017 has been an exceptionally productive period for us in R&D as we announced top-line data for our three JZP-110 Phase 3 studies and our Xyrem Phase 2/3 pediatric study, completed the Vyxeos NDA submission while preparing for potential FDA approval and launch, started additional clinical programs and advanced other key development projects,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. “With increased clarity around Xyrem longevity, we remain focused on delivering on our growth strategy, including preparing for the launch of additional products, such as Vyxeos, and investing in corporate development activities with the goal of further diversifying and expanding our product portfolio and offering important new therapeutic options to patients while increasing shareholder value.”
GAAP net income for the first quarter of 2017 was $86.5 million, or $1.41 per diluted share, compared to $75.8 million, or $1.21 per diluted share, for the first quarter of 2016.
Adjusted net income for the first quarter of 2017 was $141.2 million, or $2.31 per diluted share, compared to $134.6 million, or $2.15 per diluted share, for the first quarter of 2016. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Financial Highlights
Three Months Ended March 31, | ||||||||||
(In thousands, except per share amounts and percentages) | 2017 | 2016 | Change | |||||||
Total revenues | $ | 376,053 | $ | 336,010 | 11.9 | % | ||||
GAAP net income | $ | 86,511 | $ | 75,812 | 14.1 | % | ||||
Adjusted net income | $ | 141,222 | $ | 134,568 | 4.9 | % | ||||
GAAP EPS | $ | 1.41 | $ | 1.21 | 16.5 | % | ||||
Adjusted EPS | $ | 2.31 | $ | 2.15 | 7.4 | % | ||||
1
Total Revenues
Three Months Ended March 31, | |||||||
(In thousands) | 2017 | 2016 | |||||
Xyrem® (sodium oxybate) oral solution | $ | 272,326 | $ | 249,537 | |||
Erwinaze® / Erwinase® (asparaginase Erwinia chrysanthemi) | 51,388 | 51,173 | |||||
Defitelio® (defibrotide sodium) / defibrotide | 35,900 | 17,897 | |||||
Prialt® (ziconotide) intrathecal infusion | 7,717 | 6,209 | |||||
Other | 6,347 | 9,100 | |||||
Product sales, net | 373,678 | 333,916 | |||||
Royalties and contract revenues | 2,375 | 2,094 | |||||
Total revenues | $ | 376,053 | $ | 336,010 | |||
Net product sales increased 12% in the first quarter of 2017 compared to the same period in 2016 primarily due to higher net product sales of Xyrem and Defitelio.
Xyrem net product sales increased 9% in the first quarter of 2017 compared to the same period in 2016.
Erwinaze/Erwinase net product sales in the first quarter of 2017 were consistent with net product sales in the same period in 2016. During the quarter, the company continued to experience supply challenges, which resulted in fluctuations in inventory levels and temporary disruptions to the company's ability to supply certain markets. The company expects that temporary supply disruptions will continue in 2017, including in the U.S.
Defitelio/defibrotide net product sales increased 101% in the first quarter of 2017 compared to the same period in 2016 primarily due to the launch of Defitelio in the U.S. in April 2016 and strong growth in sales in other markets. Net product sales in the U.S. were $11.6 million in the first quarter of 2017.
Operating Expenses
Three Months Ended March 31, | |||||||
(In thousands, except percentages) | 2017 | 2016 | |||||
GAAP: | |||||||
Cost of product sales | $ | 25,065 | $ | 23,439 | |||
Gross margin | 93.3 | % | 93.0 | % | |||
Selling, general and administrative | $ | 144,255 | $ | 128,765 | |||
% of total revenues | 38.4 | % | 38.3 | % | |||
Research and development | $ | 44,928 | $ | 31,252 | |||
% of total revenues | 11.9 | % | 9.3 | % | |||
Acquired in-process research and development | $ | — | $ | 8,750 | |||
2
Three Months Ended March 31, | |||||||
(In thousands, except percentages) | 2017 | 2016 | |||||
Non-GAAP adjusted: | |||||||
Cost of product sales | $ | 23,819 | $ | 22,640 | |||
Gross margin | 93.6 | % | 93.2 | % | |||
Selling, general and administrative | $ | 118,450 | $ | 102,611 | |||
% of total revenues | 31.5 | % | 30.5 | % | |||
Research and development | $ | 40,786 | $ | 27,962 | |||
% of total revenues | 10.8 | % | 8.3 | % | |||
Operating expenses changed over the prior year period primarily due to the following:
• | Selling, general and administrative (SG&A) expenses increased in the first quarter of 2017 compared to the same period in 2016 on a GAAP and on a non-GAAP adjusted basis primarily due to higher headcount and other expenses resulting from the expansion of the company’s business, including expenses related to the potential U.S. launch of VyxeosTM (cytarabine and daunorubicin liposome injection). |
• | Research and development (R&D) expenses increased in the first quarter of 2017 compared to the same period in 2016 on a GAAP and on a non-GAAP adjusted basis and included costs related to the completion of the rolling new drug application (NDA) submission for Vyxeos; increased expenses for continued investments in oxybate-related R&D programs, including the initiation of a clinical study of JZP-258; and an increase in headcount required to support these activities. |
Cash Flow and Balance Sheet
As of March 31, 2017, cash, cash equivalents and investments were $407.0 million, and the outstanding principal balance of the company’s long-term debt was $2.0 billion. During the first quarter of 2017, the company made a $150.0 million repayment of borrowings under the company's revolving credit facility and used $13.9 million to repurchase approximately 118,000 ordinary shares under the company's share repurchase program at an average cost of $117.65 per ordinary share. Cash flows from operations were $164.5 million in the first quarter of 2017.
Recent Developments
In March 2017, the company enrolled the first patient in a Phase 3 clinical study evaluating JZP-258, an investigational oxybate product candidate with 90 percent less sodium content than Xyrem, for the treatment of cataplexy and excessive daytime sleepiness in adult narcolepsy patients with cataplexy.
In March and April 2017, the company announced positive efficacy and top-line safety results from the global Phase 3 studies evaluating JZP-110 for the treatment of excessive sleepiness in adult patients with obstructive sleep apnea (TONES 3 and TONES 4) and for the treatment of excessive sleepiness in adult patients with narcolepsy (TONES 2).
In March 2017, the company entered into license agreements with Nippon Shinyaku Co., Ltd. for the development and commercialization of Defitelio and Vyxeos in Japan.
On March 31, 2017, the company completed the rolling submission of an NDA to the U.S. Food and Drug Administration (FDA) for Vyxeos, an investigational treatment for acute myeloid leukemia.
In April 2017, the company entered into agreements with Hikma Pharmaceuticals PLC (Hikma) resolving the company's patent litigation with Hikma related to Xyrem.
3
In April 2017, the company announced positive efficacy and top-line safety results from the global Phase 2/3 study evaluating Xyrem for the treatment of cataplexy in pediatric patients with narcolepsy.
2017 Financial Guidance
Jazz Pharmaceuticals is updating its full year 2017 financial guidance as follows (in millions, except per share amounts and percentages):
Revenues | $1,625-$1,700 |
Total net product sales | $1,617-$1,692 |
-Xyrem net sales* | $1,200-$1,230 |
-Erwinaze/Erwinase net sales | $205-$225 |
-Defitelio/defibrotide net sales | $130-$150 |
-Vyxeos (CPX-351) net sales1 | $10-$20 |
GAAP gross margin % | 93% |
Non-GAAP adjusted gross margin %2,5 | 93% |
GAAP SG&A expenses* | $521-$556 |
Non-GAAP adjusted SG&A expenses3,5 | $440-$460 |
GAAP R&D expenses* | $185-$216 |
Non-GAAP adjusted R&D expenses4,5 | $165-$180 |
GAAP net income per diluted share | $6.55-$7.55 |
Non-GAAP adjusted net income per diluted share5 | $10.70-$11.30 |
____________________________
* Updated May 9, 2017.
1. | Guidance assumes FDA approval and launch of Vyxeos (CPX-351) in the U.S. in 2017. |
2. | Excludes $5 million of share-based compensation expense from estimated GAAP gross margin. |
3. | Excludes $75-$90 million of share-based compensation expense and $6 million of expenses related to certain legal proceedings and restructuring from estimated GAAP SG&A expenses. |
4. | Excludes $20-$25 million of share-based compensation expense and $0-$11 million of milestone payments from estimated GAAP R&D expenses. |
5. | See “Non-GAAP Financial Measures” below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the table titled "Reconciliation of GAAP to Non-GAAP Adjusted 2017 Net Income Guidance" at the end of this press release. |
Conference Call Details
Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EDT (9:30 p.m. IST) to provide a business and financial update and discuss its 2017 first quarter results. The live webcast may be accessed from the Investors & Media section of the company’s website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing +1 855 353 7924 in the U.S., or +1 503 343 6056 outside the U.S., and entering passcode 6947297.
A replay of the conference call will be available through May 16, 2017 by dialing +1 855 859 2056 in the U.S., or +1 404 537 3406 outside the U.S., and entering passcode 6947297. An archived version of the webcast will be available for at least one week in the Investors & Media section of the company's website at www.jazzpharmaceuticals.com.
4
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi) and Defitelio® (defibrotide sodium) in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com.
Non-GAAP Financial Measures
To supplement Jazz Pharmaceuticals’ financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this press release and the accompanying tables. In particular, the company presents non-GAAP adjusted net income (and the related per share measure) and its line item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (and the related per share measure) and its line item components exclude from reported GAAP net income (and the related per share measure) and its line item components certain items, as detailed in the reconciliation tables that follow, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of non-GAAP adjustments. In this regard, the components of non-GAAP adjusted net income, including non-GAAP cost of product sales, non-GAAP selling, general and administrative expenses and non-GAAP research and development expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure.
The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company’s financial information prepared in accordance with GAAP, can enhance investors’ and analysts' ability to meaningfully compare the company’s results from period to period and to its forward-looking guidance, and to identify operating trends in the company’s business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company’s financial performance. Jazz Pharmaceuticals’ management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company’s business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals’ management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions.
These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company’s condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.
5
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals’ future financial and operating results, including 2017 financial guidance, potential FDA approval and launch of Vyxeos in the U.S. in 2017, the company’s growth strategy, including preparing for the launch of additional products and investing in corporate development activities with the goal of further diversifying and expanding the company's product portfolio and offering important new therapeutic options to patients while increasing shareholder value, the company’s expectation for continuing Erwinaze supply disruptions and other statements that are not historical facts. These forward-looking statements are based on the company’s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of and revenue from Xyrem, such as the potential U.S. introduction of a generic version of Xyrem before the entry dates specified in the settlements with certain companies or on terms that are different from those contemplated by the settlements; ongoing patent litigation and related proceedings; effectively commercializing the company’s other products and product candidates; the regulatory approval process, including the risk that the company may be unable to obtain FDA approval for Vyxeos in the U.S. in 2017 or at all; protecting and enhancing the company’s intellectual property rights; delays or problems in the supply or manufacture of the company’s products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements; government investigations and other actions; obtaining and maintaining appropriate pricing and reimbursement for the company’s products; pharmaceutical product development and the uncertainty of clinical success; identifying and acquiring, in-licensing or developing additional products or product candidates, financing these transactions and successfully integrating acquired businesses; potential restrictions on the company’s ability and flexibility to pursue share repurchases and future strategic opportunities as a result of its substantial outstanding debt obligations; and the ability to achieve expected future financial performance and results; and other risks and uncertainties affecting the company, including those described from time to time under the caption “Risk Factors” and elsewhere in Jazz Pharmaceuticals plc’s Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company’s Annual Report on Form 10-K for the year ended December 31, 2016 and future filings and reports by the company, including the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. Other risks and uncertainties of which the company is not currently aware may also affect the company’s forward-looking statements and may cause actual results and timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the company on its website or otherwise. The company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
6
JAZZ PHARMACEUTICALS PLC
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Revenues: | |||||||
Product sales, net | $ | 373,678 | $ | 333,916 | |||
Royalties and contract revenues | 2,375 | 2,094 | |||||
Total revenues | 376,053 | 336,010 | |||||
Operating expenses: | |||||||
Cost of product sales (excluding amortization of intangible assets) | 25,065 | 23,439 | |||||
Selling, general and administrative | 144,255 | 128,765 | |||||
Research and development | 44,928 | 31,252 | |||||
Acquired in-process research and development | — | 8,750 | |||||
Intangible asset amortization | 25,665 | 22,642 | |||||
Total operating expenses | 239,913 | 214,848 | |||||
Income from operations | 136,140 | 121,162 | |||||
Interest expense, net | (18,844 | ) | (12,192 | ) | |||
Foreign exchange loss | (1,464 | ) | (819 | ) | |||
Income before income tax provision and equity in loss of investee | 115,832 | 108,151 | |||||
Income tax provision | 29,160 | 32,339 | |||||
Equity in loss of investee | 161 | — | |||||
Net income | $ | 86,511 | $ | 75,812 | |||
Net income per ordinary share: | |||||||
Basic | $ | 1.44 | $ | 1.24 | |||
Diluted | $ | 1.41 | $ | 1.21 | |||
Weighted-average ordinary shares used in per share calculations - basic | 59,880 | 61,142 | |||||
Weighted-average ordinary shares used in per share calculations - diluted | 61,178 | 62,616 | |||||
7
JAZZ PHARMACEUTICALS PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
March 31, 2017 | December 31, 2016 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 346,995 | $ | 365,963 | |||
Investments | 60,000 | 60,000 | |||||
Accounts receivable, net of allowances | 243,035 | 234,244 | |||||
Inventories | 37,653 | 34,051 | |||||
Prepaid expenses | 38,118 | 24,501 | |||||
Other current assets | 27,052 | 29,310 | |||||
Total current assets | 752,853 | 748,069 | |||||
Property and equipment, net | 119,913 | 107,490 | |||||
Intangible assets, net | 2,998,780 | 3,012,001 | |||||
Goodwill | 899,290 | 893,810 | |||||
Deferred tax assets, net, non-current | 18,038 | 15,060 | |||||
Deferred financing costs | 9,325 | 9,737 | |||||
Other non-current assets | 17,625 | 14,060 | |||||
Total assets | $ | 4,815,824 | $ | 4,800,227 | |||
LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 29,144 | $ | 22,415 | |||
Accrued liabilities | 183,645 | 193,268 | |||||
Current portion of long-term debt | 136,094 | 36,094 | |||||
Income taxes payable | 35,300 | 4,506 | |||||
Deferred revenue | 8,590 | 1,123 | |||||
Total current liabilities | 392,773 | 257,406 | |||||
Deferred revenue, non-current | 22,624 | 2,601 | |||||
Long-term debt, less current portion | 1,739,594 | 1,993,531 | |||||
Deferred tax liability, net, non-current | 548,038 | 556,733 | |||||
Other non-current liabilities | 128,809 | 112,617 | |||||
Total shareholders’ equity | 1,983,986 | 1,877,339 | |||||
Total liabilities and shareholders’ equity | $ | 4,815,824 | $ | 4,800,227 | |||
8
JAZZ PHARMACEUTICALS PLC
SUMMARY OF CASH FLOWS
(In thousands)
(Unaudited)
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
Net cash provided by operating activities | $ | 164,540 | $ | 151,654 | |||
Net cash used in investing activities | (3,574 | ) | (11,995 | ) | |||
Net cash used in financing activities | (181,674 | ) | (152,458 | ) | |||
Effect of exchange rates on cash and cash equivalents | 1,740 | 3,794 | |||||
Net decrease in cash and cash equivalents | $ | (18,968 | ) | $ | (9,005 | ) | |
JAZZ PHARMACEUTICALS PLC
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended March 31, | |||||||
2017 | 2016 | ||||||
GAAP reported net income | $ | 86,511 | $ | 75,812 | |||
Intangible asset amortization | 25,665 | 22,642 | |||||
Share-based compensation expense | 25,193 | 24,183 | |||||
Upfront and milestone payments | — | 8,750 | |||||
Expenses related to certain legal proceedings and restructuring | 6,000 | 6,060 | |||||
Non-cash interest expense | 5,615 | 5,362 | |||||
Income tax effect of adjustments (1) | (7,762 | ) | (8,241 | ) | |||
Non-GAAP adjusted net income | $ | 141,222 | $ | 134,568 | |||
GAAP reported net income per diluted share | $ | 1.41 | $ | 1.21 | |||
Non-GAAP adjusted net income per diluted share | $ | 2.31 | $ | 2.15 | |||
Weighted-average ordinary shares used in diluted per share calculations | 61,178 | 62,616 | |||||
_____________________________
(1) | The income tax effect of the adjustments between GAAP reported and non-GAAP adjusted net income takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). |
9
JAZZ PHARMACEUTICALS PLC
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS AND OTHER INFORMATION
(In thousands, except per share amounts and percentages)
(Unaudited)
Three Months Ended | |||||||||||||||||||||||
March 31, 2017 | March 31, 2016 | ||||||||||||||||||||||
GAAP Reported | Adjustments | Non-GAAP Adjusted | GAAP Reported | Adjustments | Non-GAAP Adjusted | ||||||||||||||||||
Total revenues | $ | 376,053 | $ | — | $ | 376,053 | $ | 336,010 | $ | — | $ | 336,010 | |||||||||||
Cost of product sales (excluding amortization of intangible assets) | 25,065 | (1,246 | ) | (a) | 23,819 | 23,439 | (799 | ) | (a) | 22,640 | |||||||||||||
Selling, general and administrative | 144,255 | (25,805 | ) | (b) | 118,450 | 128,765 | (26,154 | ) | (b) | 102,611 | |||||||||||||
Research and development | 44,928 | (4,142 | ) | (c) | 40,786 | 31,252 | (3,290 | ) | (c) | 27,962 | |||||||||||||
Acquired in-process research and development | — | — | — | 8,750 | (8,750 | ) | — | ||||||||||||||||
Intangible asset amortization | 25,665 | (25,665 | ) | — | 22,642 | (22,642 | ) | — | |||||||||||||||
Interest expense, net | 18,844 | (5,615 | ) | (d) | 13,229 | 12,192 | (5,362 | ) | (d) | 6,830 | |||||||||||||
Foreign currency loss | 1,464 | — | 1,464 | 819 | — | 819 | |||||||||||||||||
Income before income tax provision and equity in loss of investee | 115,832 | 62,473 | (e) | 178,305 | 108,151 | 66,997 | (e) | 175,148 | |||||||||||||||
Income tax provision | 29,160 | 7,762 | (f) | 36,922 | 32,339 | 8,241 | (f) | 40,580 | |||||||||||||||
Effective tax rate (g) | 25.2 | % | 20.7 | % | 29.9 | % | 23.2 | % | |||||||||||||||
Equity in loss of investee | 161 | — | 161 | — | — | — | |||||||||||||||||
Net income | $ | 86,511 | $ | 54,711 | (h) | $ | 141,222 | $ | 75,812 | $ | 58,756 | (h) | $ | 134,568 | |||||||||
Net income per diluted share | $ | 1.41 | $ | 2.31 | $ | 1.21 | $ | 2.15 | |||||||||||||||
_____________________________
Explanation of Adjustments and Certain Line Items (in thousands):
(a) | Share-based compensation expense of $1,246 and $689 and expenses related to certain legal proceedings and restructuring of $0 and $110 for the three months ended March 31, 2017 and 2016, respectively. |
(b) | Share-based compensation expense of $19,805 and $20,204 and expenses related to certain legal proceedings and restructuring of $6,000 and $5,950 for the three months ended March 31, 2017 and 2016, respectively. |
(c) | Share-based compensation expense of $4,142 and $3,290 for the three months ended March 31, 2017 and 2016, respectively. |
(d) | Non-cash interest expense associated with debt discount and debt issuance costs for the respective three-month period. |
(e) | Sum of adjustments (a) through (d) plus the adjustments for acquired in-process research and development and intangible asset amortization for the respective three-month period. |
(f) | Income tax effect of the adjustments between GAAP reported and non-GAAP adjusted net income takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s) for the respective three-month period. |
(g) | Income tax provision divided by income before income tax provision and equity in loss of investee for the respective three-month period. |
(h) | Net of adjustments (e) and (f) for the respective three-month period. |
10
JAZZ PHARMACEUTICALS PLC
RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2017 NET INCOME GUIDANCE
(In millions, except per share amounts)
(Unaudited)
GAAP net income | $400 - $460 |
Intangible asset amortization | 130 - 165 |
Share-based compensation expense | 100 - 120 |
Milestone payments* | 0 - 11 |
Expenses related to certain legal proceedings and restructuring* | 6 |
Non-cash interest expense | 20 - 25 |
Income tax effect of adjustments | (40) - (60) |
Non-GAAP adjusted net income | $650 - $690 |
GAAP net income per diluted share | $6.55-$7.55 |
Non-GAAP adjusted net income per diluted share | $10.70-$11.30 |
Weighted-average ordinary shares used in per share calculations | 61 |
_____________________________
* Updated May 9, 2017.
Contacts:
Investors
Kathee Littrell
Vice President, Investor Relations
Jazz Pharmaceuticals plc
Ireland, +353 1 634 7887
U.S., +1 650 496 2717
Jacqueline Kirby
Vice President, Corporate Affairs & Government Relations
Jazz Pharmaceuticals plc
Ireland, +353 1 697 2141
U.S., +1 215 867 4910
11